Results from the Göteborg-2 Prostate Cancer Screening Trial
Vincent Gnanapragasam, Chair in Urology at the University of Cambridge and an Honorary Consultant Urologist at Addenbrooke’s Hospital, shared a post on X about a recent paper titled “Prostate Cancers in the Prostate-specific Antigen Interval of 1.8–3 ng/ml: Results from the Göteborg-2 Prostate Cancer Screening Trial” published in European Urology.
Authors: Fredrik Möller, Marianne Månsson, Jonas Wallström, Mikael Hellström, Jonas Hugosson, Rebecka Arnsrud Godtman.
“So PSA and MRI in low PSA (or MRI screening) lets break it down…a little. . Prostate Cancers in the Prostate-specific Antigen Interval of 1.8–3 ng/ml: Results from the Göteborg-2 Prostate Cancer Screening Trial – European Urology.
670 men with PSA 1.8-3.0.
MRI in all.
PIRADS 3-5 in 160 (24%).
PIRADS 4-5 in 108 (16.1%).
Presume all organ confined Biopsies performed in 156 (23%).
Benign/no cancer in 606 (90.4% of n=670).
Any cancer in 9.5%.
Grade Group 1 in 33 (4.9%).
Grade Group 2 or more in 31 (4.6%).
Grade Group 3 or more in 7 (1.0%).
Therefore (assuming we don’t want to detect GG 1).
639 unnecesary MRI (95% of MRI done in this cohort).
125 unnecessary biopsies (80% of biopsies done).
To detect a 1% incidence of cancers that definitely need treating.
4.6% if we are determined to radically treat all GG2.
Would they have eventually been detected by PSA>3. Yes.
– IMO its clear : MRI should not be used as a screening tool.
– Congrats to authors.
Oh and we can look at 15 yr survival estm survival gain from treatment : using Predict Prostate.
Based on median PSA 0.7, Age 58,stage T2, and no co-morbidity (no bx info).
The 33 GG1- 3% gain vs 9% risk of OCM.
The 24 GG2 -4% gain vs 9% OCM.
The 4 GG3 – 6% gain vs 9% OCM.”
Source: Vincent Gnanapragasam/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023